BIIB240628C227500
- 2.67
- 0.000.00%
Biogen Newsroom
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
Express News | Biogen Completes Acquisition of Human Immunology Biosciences
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com
By Anita Hamilton A federal indictment of a lead scientist working as an advisor for Cassava Sciences, which has an Alzheimer's drug in late-stage clinical trials, sent shares sharply down Friday. T
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Needham analyst Ami Fadia maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $294.According to TipRanks data, the analyst has a success rate of 43.9% and a total average
Express News | Weiyuan China: Will launch a medical insurance plan for a new pharmaceutical Lunakane monoclonal antibody for Alzheimer's disease.
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
Biogen (BIIB) said Thursday it has launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi in China with Eisai Co. Ltd. Leqembi received approval in January as a treatm
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Forecasting The Future: 19 Analyst Projections For Biogen
Throughout the last three months, 19 analysts have evaluated Biogen (NASDAQ:BIIB), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shedd
Is Biogen Stock Underperforming the Nasdaq?
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 41.44% RBC Capital $317 → $317 Reiterates Outperform → Outperform 06/05/2024 41.44% RBC Capital
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $317
RBC Capital analyst Brian Abrahams maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $317.According to TipRanks data, the analyst has a success rate of 49.2% and a total
'Biogen Has Up To $10B For Its Next M&A Bets' - Bloomberg News
'Biogen Has Up To $10B For Its Next M&A Bets' - Bloomberg News
Biogen Inc. (BIIB) Is a Top-Ranked Momentum Stock: Should You Buy?
Express News | Tofidence™ (Tocilizumab), a Biosimilar Referencing Roactemra®, Approved in the European Union
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $240
Wells Fargo analyst Mohit Bansal maintains $Biogen(BIIB.US)$ with a hold rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 59.3% and a total